Targeted prostate biopsy in the diagnosis of prostate cancer: results from a prospective cohort study

Cover Page

Cite item

Full Text

Abstract

Background. Detection of prostate cancer by various targeting methods of prostate biopsy is an important problem now. Aim. To improve the detection of prostate cancer (PCa), compare the methods of targeted biopsy - cognitive biopsy guided by MRI with biopsy guided by histos-canning, using a randomized biopsy of the prostate from twelve cores as a control method. Materials and methods. A total of 145 respondents who underwent a randomized biopsy of the prostate in combination with targeted techniques were divided into 3 samples in accordance with the methods of targeted biopsy. In the results, the detectability by targeted methods was compared with each other and with a randomized biopsy as a control method. The results were subjected to statistical processing in order to form the conclusions of the study. Results. The detection rate of prostate cancer in the cognitive biopsy group was 64.4%, in the histofusion group - 51.1%, in the cognitive biopsy with histofusion group - 69% (p<0.05). The detection of PCa when comparing positive targeted biopsies did not differ statistically significantly between the methods (38 and 36%, p=0.05). The percentage of positive biopsies was higher with histofusion biopsy (34.2%) than with cognitive biopsy (29.7%), the incidence of clinically significant cancer was higher according to the results of targeted methods compared with randomized biopsy (73% vs 37.5%, p<0.05). The highest complication rate with the combined use of the studied targeting techniques was 13.6%, while all complications belonged to the 1st category according to Clavien-Dindo. Conclusion. To optimize the diagnosis of prostate cancer, it is advisable to use a combination of targeted and “randomized” cores. The combination of the targeted methods studied has been shown to be effective and safe. Carrying out a histofusion biopsy using a unified technique allows obtaining information on the clinical and morphological characteristics of prostate adenocarcinoma, which in terms of prognostic value is practically not inferior to the data of a cognitive biopsy performed taking into account the results of MRI. The use of targeted prostate biopsy methods increases the detection of clinically significant prostate cancer without adversely affecting the safety of the procedure in conjunction with standard prostate biopsy.

About the authors

Artem V. Okishev

Spasokukotsky City Clinical Hospital

Email: okishev.art@gmail.com
уролог Москва, Россия

Alexander V. Govorov

Yevdokimov Moscow State University of Medicine and Dentistry

д-р мед. наук, проф. каф. урологии Москва, Россия

Alexander O. Vasilyev

Yevdokimov Moscow State University of Medicine and Dentistry

канд. мед. наук, ассистент каф. урологии Москва, Россия

Anton V. Sadchenko

Spasokukotsky City Clinical Hospital

канд. мед. наук, уролог Москва, Россия

Konstantin B. Kolontarev

Yevdokimov Moscow State University of Medicine and Dentistry

д-р мед. наук, проф. каф. урологии Москва, Россия

Alexey V. Bormotin

Yevdokimov Moscow State University of Medicine and Dentistry

канд. мед. наук, доц. каф. урологии Москва, Россия

Yuriy A. Kim

Spasokukotsky City Clinical Hospital; Yevdokimov Moscow State University of Medicine and Dentistry

аспирант каф. урологии Москва, Россия

Boris A. Kizun

Yevdokimov Moscow State University of Medicine and Dentistry; Medical and Sanitary Unit of the Ministry of Internal Affairs of the Russian Federation for the City of Moscow

аспирант каф. урологии Москва, Россия

Kerim K. Ramazanov

Spasokukotsky City Clinical Hospital; Yevdokimov Moscow State University of Medicine and Dentistry

аспирант каф. урологии Москва, Россия

Dmitriy Y Pushkar

Yevdokimov Moscow State University of Medicine and Dentistry

акад. РАН, д-р мед. наук, зав. каф. урологии Москва, Россия

References

  1. Available from: https://gco.iarc.fr/today/
  2. Available from: https://gco.iarc.fr/today/online-analysis-table
  3. Available from: https://gco.iarc.fr/tomorrow/graphic-line
  4. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology 2019.
  5. Barentsz JO, Richenberg J, Clements R et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22:746-57.
  6. Weinreb JC, Barentsz JO, Choyke PL et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015. Version 2. Eur Urol 2016; 69 (1): 16-40.
  7. Turkbey B et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019; 76 (3): 340-51.
  8. Thompson JE, Moses D, Shnier R et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol 2014; 192: 67-74.
  9. Rouviere O et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 2019; 20: 100.
  10. Kasivisvanathan V et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 2018; 378: 1767.
  11. Van der Leest M et al. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multipara-metric Prostate Resonance Imaging with Subsequent Magnetic Resonance guided Biopsy in Biopsy-naive Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol 2019; 75: 570.
  12. Braeckman J, Autier P, Garbar C et al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int 2008; 101: 293-8.
  13. Javed S, Chadwick E, Edwards AA et al. Does prostate HistoScanningTM play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. BJU Int 2014; 114 (4): 541-8.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies